Cingulate Inc
NASDAQ:CING
During the last 3 months Cingulate Inc insiders bought 166.7k USD , and have not sold any shares. The stock price has increased by 79% over this period ( loading = false, 5000)" href="https://www.alphaspread.com/comparison/nasdaq/cing/vs/indx/gspc">open performance analysis).
The last transaction was made on
Feb 6, 2026
by
Brams Matthew
(Chief Executive Officer)
, who
bought
9.8k USD
worth of
CING shares.
During the last 3 months Cingulate Inc insiders bought 166.7k USD , and have not sold any shares. The stock price has increased by 79% over this period ( loading = false, 5000)" href="https://www.alphaspread.com/comparison/nasdaq/cing/vs/indx/gspc">open performance analysis).
The last transaction was made on
Feb 6, 2026
by
Brams Matthew
(Chief Executive Officer)
, who
bought
9.8k USD
worth of
CING shares.
Cingulate Inc
Glance View
Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The company is headquartered in Kansas City, Kansas. The company went IPO on 2021-10-07. The firm is focused on the development, manufacturing and commercialization of pharmaceutical products that utilize precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles that improves the lives of patients suffering from a multitude of commonly diagnosed conditions. The company focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The firm is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). Its CTx-1301 and CTx-1302 drug candidates both contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form. Its CTx-1301 and CTx-1302 that are being developed for the treatment of ADHD, in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+).
What is Insider Trading?
Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.
While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.
Why is Insider Trading Important?
It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.
However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.
Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.